Satellos Bioscience Inc. Common Stock (MSLE : NASDAQ)
Common Stock
$9.30
USD
+0.00 (%)
Last updated: 2026-09-17
Get MSLE alerts:
MSLE
Satellos Bioscience Inc. Common Stock
WealthAwesomePerformance
1 Day
-0.64%
1 Week
-7.19%
1 Month
-6.44%
YTD
+58.97%
Key Statistics
Market Cap
$197.31M
52W High
$13.39
52W Low
$5.30
P/E Ratio
-
50 Day MA
$9.49
200 Day MA
$8.23
Beta
1.14
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $9.27 | $9.76 | $9.27 | $9.68 | $9.68 | 17,015 |
| 9/16/2026 | $9.50 | $9.66 | $9.19 | $9.30 | $9.30 | 29,472 |
| 9/15/2026 | $9.70 | $9.70 | $9.33 | $9.36 | $9.36 | 16,859 |
| 9/14/2026 | $9.76 | $10.00 | $9.76 | $9.79 | $9.79 | 7,735 |
| 9/11/2026 | $10.13 | $10.29 | $9.44 | $9.75 | $9.75 | 33,718 |
| 9/10/2026 | $10.13 | $10.50 | $9.82 | $10.05 | $10.05 | 47,200 |
| 9/9/2026 | $9.45 | $10.47 | $9.27 | $10.02 | $10.02 | 72,600 |
| 9/8/2026 | $9.00 | $9.55 | $8.91 | $9.18 | $9.18 | 82,300 |
| 9/4/2026 | $9.13 | $9.25 | $8.95 | $8.97 | $8.97 | 25,600 |
| 9/3/2026 | $9.13 | $9.38 | $8.96 | $9.08 | $9.08 | 27,500 |
Analyst Price Targets
Based on analyst covering MSLE · as of Sep 17, 2026
Wall Street analysts forecast MSLE stock price to rise 182.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$26.25
+182.3% Upside
Current Price
US$9.30
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSLE's historical volatility
30-Day Vol
57.1%
Annualized
90-Day Vol
75.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$11.57
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$10.27 | US$8.44 – US$12.51 |
| 60 trading days | US$10.90 | US$8.25 – US$14.41 |
| 90 trading days | US$11.57 | US$8.23 – US$16.28 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-35.82M
- Profit Margin
- 0.00%
- ROE (TTM)
- -70.45%
- EPS (Diluted)
- -1.95
- Book Value
- 2.88
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About MSLE.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |